CEO and CFO of Probi AB (publ) acquires shares

Tom Rönnlund, CEO of Probi AB (publ), has acquired 1,000 shares in Probi AB on May 2, 2019. After the transaction Tom Rönnlund holds a total of 1,000 shares. The same day Henrik Lundkvist, CFO of Probi AB (publ), has acquired 150 shares in Probi AB. After the transaction Henrik Lundkvist holds a total of 150 shares.

The transactions have been reported to the Swedish Financial Supervisory authority.

FOR FURTHER INFORMATION, CONTACT:
Henrik Lundkvist, CFO, Probi, tel +46 46 286 89 41, e-mail: henrik.lundkvist@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. Probi’s vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2018, Probi had net sales of MSEK 604. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi had about 4,000 shareholders on December 31, 2018. Read more at www.probi.com. 

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Subscribe

Documents & Links